Edition:
United Kingdom

People: Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

0.51USD
9:00pm BST
Change (% chg)

$-0.00 (-0.85%)
Prev Close
$0.52
Open
$0.52
Day's High
$0.52
Day's Low
$0.51
Volume
1,343,130
Avg. Vol
2,911,493
52-wk High
$2.58
52-wk Low
$0.49

Erck, Stanley 

Mr. Stanley C. Erck is President, Chief Executive Officer, Director of the Company. He was President, Chief Executive Officer, Director of Novavax, Inc. since April 2011. Former Executive Chairman of Novavax, Inc. from February 2010 until April 2011, and a Director since June 2009. From 2000 to 2008, Mr. Erck served as President, Chief Executive Officer and Director of Iomai Corporation, a vaccine development company, which was acquired in 2008 by Intercell. Prior to that, Mr. Erck previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International. Mr. Erck serves as a member of the boards of BioCryst Pharmaceuticals, Inc. (BCRX), MaxCyte, Inc., and MDBio Foundation. Mr. Erck received a B.S. in economics from the University of Illinois and a M.B.A from the University of Chicago.

Basic Compensation

Total Annual Compensation, USD 1,007,760
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,763,920
Fiscal Year Total, USD 2,771,680

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 400,000 1,563,120.00
Name Fiscal Year Total

James Young

533,780

Stanley Erck

2,771,680

John Trizzino

947,747

Gregory Glenn

1,221,250

John Herrmann

913,317

Jody Lichaa

--
As Of  31 Dec 2017